Ellex Announces Appointment of President, Ellex iTrack™

Adelaide, Australia, 11 July 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced the appointment of Mr. Joaquin Wolff to the position of President, Ellex iTrack™. In this newly created position Mr. Wolff expands the Company’s executive management team and will be dedicated to managing the Ellex iTrack™ business in the rapidly growing minimally invasive glaucoma surgery (MIGS) device market. He will be based out of Ellex iTrack™ headquarters in Fremont in the San Francisco Bay area. Mr. Wolff is a recognized expert in the ophthalmic
Read More

Appointment of Directors

Adelaide, Australia, 2 July 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced the appointment of two new Directors to the Board, Mr. Mike Southard and Mr. Mike Mangano. The appointment will be ratified, by resolution, at the company’s next AGM. Mike Southard Mike Southard spent 25 years with the world’s largest ophthalmology company, Alcon Laboratories of Fort Worth Texas, as Vice President of the Global Surgical business. During Mike’s tenure, the Alcon business grew dramatically from US$85 million to US$2.4 billion of sales per year.
Read More

Ellex iTrack and Ellex Glaucoma Business Third Quarter Sales Update

 Highlights:  • Sales of Ellex iTrackTM up 57% in the USA and 40% globally compared with the pcp  • Improved new customer acquisition and revenues for Ellex iTrackTM in all but one US territory demonstrates improved geographic penetration  • Global sales of Ellex glaucoma business reached a record US$22.3 million with an acceleration to 40% growth compared with the pcp  Adelaide, Australia 16 April 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced a sales update for Ellex iTrackTM, and its wider glaucoma business, for the
Read More

Ellex’s Patented Glaucoma Treatment Technologies to be Spotlighted at Major US Tradeshow, ASCRS 2018

Adelaide, Australia 10 April 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that it will showcase its proprietary glaucoma treatment portfolio, including its breakthrough iTrack™ minimally invasive glaucoma surgery (MIGS) technology, at the 2018 annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) in Washington, 13-17 April 2018. Also on display will be Ellex’s proprietary Reflex Technology™ for the treatment of symptomatic floater patients.  With more than 9000 members, the ASCRS is considered to be the preeminent educational society for anterior segment
Read More

2RT to Feature at European Laser Innovation Forum 2018

Adelaide, Australia 23 March 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced the agenda for a panel discussion on the Company’s proprietary 2RT® Retinal Rejuvenation Therapy at the European Laser Innovation Forum to be held in Nice, France on 24 March 2018. 2RT® is Ellex’s breakthrough laser therapy which has the potential to positively influence the lives of millions of people suffering from age-related macular degeneration (AMD) in its early stages. An interventional treatment, 2RT® may allow physicians to treat patients at a stage of
Read More

Additional Financial Information on Segment Results for the half year ended 31 December 2017

Adelaide, Australia 9 March 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today provided detailed information on the profit and loss for each business segment. This provides investors with greater understanding of the investment being made in Ellex iTrack™ sales and marketing and the impact on the financial results. This information is attached and can be read in conjunction with the consolidated financial results for the half year ended 31 December 2017 issued on 27 February 2018. View the profit and loss statement here   ABOUT ELLEX
Read More

Ellex at American Glaucoma Society Meeting, New York City

Adelaide, Australia 7 March 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that the company has successfully showcased its glaucoma products at the American Glaucoma Society (AGS) 2018 Annual Meeting in New York City, 1-3 March 2018. The AGS Annual Meeting is the pre-eminent event for glaucoma specialists in the USA, comprising both a scientific program and a tradeshow exhibition. Approximately 1,100 physicians attended the 2018 meeting, an increase of 30% on the prior year, providing a strong platform for Ellex to continue its marketing
Read More

Release of Financial Results for Half-Year ended 31 December 2017

Highlights:  • Record sales revenue of A$38 million for the half achieved as Ellex’s glaucoma market penetration strategy gains traction  • Revenue and earnings in line with previous trading update  • Cash balance of A$25 million – Ellex well capitalised to grow top line revenue through glaucoma focus  • 65% uplift in USA sales of lead product Ellex iTrackTM and 9% lift in Core Laser and Ultrasound business sales resulted in 12% growth in Group sales compared with the prior corresponding period  • Revenue expected to continue to increase in the second half  Adelaide, Australia 27 February 2018 – Ellex
Read More

Trading Update for Half-Year Ended 31 December 2017

 Highlights:  • Ellex Group sales up 11.7% (13% in constant currency) compared with prior corresponding period, driven by glaucoma sales growth strategy  • Ellex iTrack™ sales up 65% in USA and 30% outside the USA in constant currency compared with prior corresponding period  • Ellex Core Laser & Ultrasound sales up 9% in constant currency compared with prior corresponding period, driven by strong glaucoma laser sales  • Glaucoma therapy device sales of A$19.8 million now comprise 50% of Ellex group revenue and are growing at a four-year CAGR of 16%  Adelaide, Australia 5 February 2018 – Ellex Medical Lasers Limited
Read More